What is IgGenix?
IgGenix is a clinical-stage antibody discovery and development company focused on addressing allergies and other immunological diseases. Utilizing their SEQ SIFTER antibody discovery platform, they develop innovative products aimed at providing effective clinical responses for both pediatric and adult patients. Their lead candidate, IGNX001, is a first-in-class antibody designed to block the allergic cascade, specifically targeting food allergies. The company conducts research and clinical trials to advance their pipeline, which includes therapies for various food and environmental allergies. By targeting the root causes of allergic reactions rather than just symptom management, IgGenix is carving out a distinct niche in the biopharmaceutical sector.
How much funding has IgGenix raised?
IgGenix has raised a total of $65M across 2 funding rounds:
Series A
$25M
Series B
$40M
Series A (2021): $25M with participation from Khosla Ventures, Matthias Westman, Alexandria Venture Investments, ShangBay Capital, and AllerFund
Series B (2023): $40M led by Eli Lilly and Company Pvt and Khosla Ventures
Key Investors in IgGenix
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on areas including health, agriculture, and enterprise AI.
Eli Lilly and Company
Eli Lilly and Company is a global biopharmaceutical leader specializing in advanced treatment options for chronic diseases, with a strong emphasis on medical and health innovations.
ShangBay Capital
ShangBay Capital is a venture capital firm specializing in medical devices, biotechnology, and healthcare, with a focus on early-stage industry growth.
What's next for IgGenix?
With the recent influx of capital, IgGenix is well-positioned to scale its clinical trial operations and further validate the efficacy of its lead candidate, IGNX001. The strategic backing from major pharmaceutical players and venture firms suggests a clear path toward commercialization and potential partnership opportunities. Moving forward, the company will likely focus on expanding its therapeutic pipeline and refining its antibody discovery platform to address a broader spectrum of immunological conditions. The focus remains on achieving key clinical milestones that will solidify its market position and provide long-term value to stakeholders in the healthcare and biotechnology sectors.
See full IgGenix company page
